Zai Lab Limited (ZLAB): Price and Financial Metrics


Zai Lab Limited (ZLAB): $43.68

-1.88 (-4.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZLAB to Watchlist
Sign Up

Industry: China


Ranked

of

in industry

ZLAB Stock Price Chart Interactive Chart >

Price chart for ZLAB

ZLAB Price/Volume Stats

Current price $43.68 52-week high $152.82
Prev. close $45.56 52-week low $22.51
Day low $43.60 Volume 126,365
Day high $45.80 Avg. volume 707,637
50-day MA $37.60 Dividend yield N/A
200-day MA $49.20 Market Cap 4.28B

Zai Lab Limited (ZLAB) Company Bio


Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. The company was founded in 2013 and is based in Shanghai, China.


ZLAB Latest News Stream


Event/Time News Detail
Loading, please wait...

ZLAB Latest Social Stream


Loading social stream, please wait...

View Full ZLAB Social Stream

Latest ZLAB News From Around the Web

Below are the latest news stories about Zai Lab Ltd that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying

In this article we present the list of Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Click to skip ahead and see the Top 5 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), and Perrigo Co Plc (NASDAQ:PRGO) were […]

Yahoo | February 20, 2022

Zai Lab''s repotrectinib for lung cancer subtype gets breakthrough therapy tag in China

Zai Lab (ZLAB) said the Center for Drug Evaluation ((CDE)) of the National Medical Products Administration ((NMPA)) granted breakthrough therapy designation to repotrectinib for…

Seeking Alpha | February 17, 2022

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

--- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumorsSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for th

Yahoo | February 17, 2022

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

-- Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the twelve months ended December 31, 2021, after the closing of the U.S. equity markets on March 1, 2022. The Company will host a

Yahoo | February 15, 2022

Quaero Capital S.A. Buys Canadian National Railway Co, Cheniere Energy Inc, CenterPoint Energy ...

Investment company Quaero Capital S.A. (Current Portfolio) buys Canadian National Railway Co, Cheniere Energy Inc, CenterPoint Energy Inc, Air Products & Chemicals Inc, NICE, sells Futu Holdings, TPI Composites Inc, Zai Lab, Farfetch, NIO Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Quaero Capital S.A..

Yahoo | February 7, 2022

Read More 'ZLAB' Stories Here

ZLAB Price Returns

1-mo 5.10%
3-mo 22.28%
6-mo -26.38%
1-year -68.86%
3-year 29.50%
5-year N/A
YTD -30.50%
2021 -53.56%
2020 225.41%
2019 79.11%
2018 9.37%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6233 seconds.